Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor

Gene Expression (GE) and MicroRNA (MIRNA) Expression Profiles of Malignant Rhabdoid Tumors (MRT) of the Kidney (RTK) and Atypical Teratoid Rhabdoid Tumor (ATRT)

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01453465

Enrollment

Registered

2011-10-17

Start date

2011-11-01

Completion date

Unknown

Last updated

2018-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Atypical Teratoid/Rhabdoid Tumor, Rhabdoid Tumor of the Kidney

Brief summary

This research trial studies biomarkers in samples from patients with rhabdoid tumor of the kidney and atypical teratoid rhabdoid tumor. Studying biomarkers of tissue samples from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer.

Detailed description

PRIMARY OBJECTIVES: I. To determine if there are molecular differences between rhabdoid tumor of the kidney (RTK) and the atypical teratoid rhabdoid tumor (ATRT). OUTLINE: Archived tumor tissue samples are analyzed for gene expression profile and microRNA profile.

Interventions

OTHERLaboratory Biomarker Analysis

Correlative studies

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Samples of RTK and ATRT provided by the Children?s Oncology Group (COG)

Design outcomes

Primary

Measure	Time frame
Molecular differences between RTK and the ATRT	Up to 3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026